Literature DB >> 10551506

Should the Mini Mental State Examination be used to monitor dementia treatments?

P Bowie, T Branton, J Holmes.   

Abstract

The test-retest and inter-rater reliabilities of the Mini Mental State Examination were found inadequate for detecting small changes in cognition, making this test inappropriate for assessing treatment response in Alzheimer's disease.

Entities:  

Mesh：

Year:  1999        PMID： 10551506     DOI： 10.1016/S0140-6736(99)03486-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  10 in total

1.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Colin Green; Joanna Picot; Emma Loveman; Andrea Takeda; Jo Kirby; Andrew Clegg
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.

Authors:  Chit Wai Wong
Journal:  Drugs Aging       Date:  2016-07       Impact factor: 3.923

3.  [Validation of the German version of the 6‑item screener : Brief cognitive test with broad application possibilities].

Authors:  S Krupp; A Seebens; J Kasper; M Willkomm; F Balck
Journal:  Z Gerontol Geriatr       Date:  2017-01-16       Impact factor: 1.281

Review 4.  Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia.

Authors:  David B Hogan; Peter Bailey; Sandra Black; Anne Carswell; Howard Chertkow; Barry Clarke; Carole Cohen; John D Fisk; Dorothy Forbes; Malcolm Man-Son-Hing; Krista Lanctôt; Debra Morgan; Lilian Thorpe
Journal:  CMAJ       Date:  2008-11-04       Impact factor: 8.262

5.  Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen Aronson; Bart Van Baelen; Shane Kavanagh; Susanne Schwalen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 6.  Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.

Authors:  Colin Green
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

7.  Cognitive Function and Brain Atrophy Predict Non-pharmacological Efficacy in Dementia: The Mihama-Kiho Scan Project2.

Authors:  Ken-Ichi Tabei; Masayuki Satoh; Jun-Ichi Ogawa; Tomoko Tokita; Noriko Nakaguchi; Koji Nakao; Hirotaka Kida; Hidekazu Tomimoto
Journal:  Front Aging Neurosci       Date:  2018-04-12       Impact factor: 5.750

8.  To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?

Authors:  Jaime Caro; Alexandra Ward; Khajak Ishak; Kristen Migliaccio-Walle; Denis Getsios; George Papadopoulos; Koen Torfs
Journal:  BMC Neurol       Date:  2002-08-19       Impact factor: 2.474

9.  Comparison of cognitive and UHDRS measures in monitoring disease progression in Huntington's disease: a 12-month longitudinal study.

Authors:  Eng A Toh; Michael R MacAskill; John C Dalrymple-Alford; Daniel J Myall; Leslie Livingston; Sandy Ad Macleod; Tim J Anderson
Journal:  Transl Neurodegener       Date:  2014-07-12       Impact factor: 8.014

10.  A correlativity study of plasma APL1β28 and clusterin levels with MMSE/MoCA/CASI in aMCI patients.

Authors:  Ying Meng; Huiying Li; Rui Hua; Huali Wang; Jian Lu; Xin Yu; Chen Zhang
Journal:  Sci Rep       Date:  2015-10-27       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.